PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

SIMPLE SUMMARY: The burden of pancreatic ductal adenocarcinoma (PDAC) increases with rising incidence, yet 5-year overall survival remains poor at 17%. Routine comprehensive genomic profiling of PDAC only finds 2.5% of patients who may benefit and receive matched targeted therapy. Protein arginine m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Michael K. C., Grimmond, Sean M., McArthur, Grant A., Sheppard, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534199/
https://www.ncbi.nlm.nih.gov/pubmed/34680285
http://dx.doi.org/10.3390/cancers13205136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534199/
https://www.ncbi.nlm.nih.gov/pubmed/34680285
http://dx.doi.org/10.3390/cancers13205136

Ejemplares similares